RN Mobile Menu

Search form




FDA boxed warnings about hepatitis B virus (HBV) reactivation risk relate only to ofatumumab and rituximab. Eminent hepatologists say everyone destined for immunosuppression should be tested for HBV first.

Clinical remission is not necessarily good reason to stop treatment for rheumatoid arthritis. New MRI data show that many patients continue to show inflammation and osteitis, even if they no longer have symptoms.

Amgen has announced success in a Phase 3 trial of an adalimumab biosimilar. The subject of biosilimars is already "trending" in state legislatures, 10 of which now mandate notification of substitution.

The newer, injectable form of tocilizumab (Actemra) appears as safe and effective as the original intravenous version for treating rheumatoid arthritis unresponsive to other therapies.

A 606-patient randomized trial from Europe finds that a glucosamine-chondroitin combination works as well as the drug celecoxib (Celebrex) for knee osteoarthritis.

psoriatic arthritis

An increase in the number of joints affected by psoriatic arthritis doesn't usually lead to changes in TNF blocker treatment, this retrospective study shows. But changes in discontinuation over time and by gender are puzzling.

The first antibody found (researchers claim) to react with both skin and joints may explain why psoriasis can progress to psoriatic arthritis. Validated, it could also improve diagnosis.


Subscribe to Arthritis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.